#USA #New York #Securities Fraud #Rosen Law Firm #Ultragenyx

Investors Encouraged to Take Action in Ultragenyx Fraud Case

In a recent announcement from the Rosen Law Firm, investors who acquired common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025 have an important opportunity to take part in a securities fraud class action lawsuit. The deadline to act as a lead plaintiff is April 6, 2026.

What the Lawsuit Entails

The lawsuit addresses allegations related to material misstatements and omissions provided by the company's executives. The claims focus on Ultragenyx's clinical trials for setrusumab (UX 143), particularly its Phase III Orbit and Cosmic Studies involving patients with Osteogenesis Imperfecta (OI). Investors were reportedly led to believe that the drug would significantly lower the annualized fracture rates in OI patients, based on exaggerated expectations regarding its effects and the design of the studies.

Financial Impact on Investors

The lawsuit claims that the misleading information led shareholders to buy stock at artificially inflated prices. When the truth came to light regarding setrusumab's actual effectiveness and the inherent risks in the study protocols, investors likely faced financial losses. The Rosen Law Firm is actively seeking stakeholders harmed during this period to join the class action.

How to Participate

Interested parties can easily join this class action by visiting this link or by calling Phillip Kim, Esq. toll-free at 866-767-3653. Investors are encouraged to act swiftly, as they must apply to the court before the deadline to be eligible to serve as a lead plaintiff. Being a lead plaintiff positions a stakeholder to represent the other class members effectively.

Importance of Experienced Legal Representation

The Rosen Law Firm emphasizes the need for qualified legal guidance in such cases. Unlike many firms that act merely as intermediaries in listings, Rosen Law Firm specializes in securities class actions and shareholder derivative litigation. With a firm track record of successful settlements, their expertise includes a notable past of achieving significant recoveries for investors, including over $438 million in one recent year. The firm has consistently ranked high among peers in terms of class action settlements.

Background on the Allegations

The core of the allegations suggests that while the company communicated overly positive forecasts about setrusumab's potential, it concurrently failed to disclose critical adverse facts. These included the reality that, despite a noted increase in bone density from the drug, it did not correlate with a reduction in fracture rates as claimed. This dissonance between expectation and reality misled investors and inflated the stock prices during the class period.

Final Note for Investors

As of now, no class has been certified, meaning that investors are not yet represented unless they choose to retain legal counsel. They have the option of remaining as absent class members, but it is important for potential participants to note that their ability to receive a shared recovery in the future is not contingent upon taking on the role of lead plaintiff.

For further updates and information, the Rosen Law Firm encourages interested individuals to follow them on platforms like LinkedIn, Twitter, and Facebook. In an environment where investor rights can be vulnerable, proactive engagement in matters of potential fraud is vital.

This is an opportunity for Ultragenyx shareholders to stand together against misleading corporate actions, and time is of the essence to protect their investments.